Evaluation of the protective effect of dexmedetomidine on patients with severe novel coronavirus pneumonia (COVID-19)

Evaluation of the protective effect of dexmedetomidine on patients with severe new coronavirus pneumonia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030853

Enrollment

Unknown

Registered

2020-03-16

Start date

2020-02-01

Completion date

Unknown

Last updated

2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Case series:dexmedetomidine

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years old; 2. Symptoms of novel coronavirus infection; 3. Positive nucleic acid test of novel coronavirus.

Exclusion criteria

Exclusion criteria: 1. Pregnancy; 2. Patients with advanced malignant tumor; 3. Suspected cases.

Design outcomes

Primary

Measure	Time frame
CK-MB;CTnI;neuron-specific enolase,NSE;BUN;scr.;lactic acid;	—

Contacts

Public ContactWen Jianli

The Third Affiliated Hospital of Zunyi Medical University

zywenjianli@163.com+86 15186660001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026